[ad_1]
Urgent clarification! Zhong Nanshan “called” Banlangen, the A + H company stock market value soared by more than 10 billion yuan, the real situation is. . . . . .
Fu Suying
Banlangen products under the “call” of Zhong Nanshan, FridayBaiyun MountainDaily limit of A share, H share soared 13.28%, the company’s market value soared by 10 billion yuan a day!
Just now, Baiyunshan issued a clarification announcement stating that the relevant conclusions involved in the relevant media reports are only the results of the in vitro detection of novel coronaviruses by the joint venture of the Baiyunshan company and the Huang Company. Compound Banlangen Granules. More work will be done in the future. There is still a certain degree of uncertainty. The sales of Compound Banlangen Granules are not expected to have a significant impact on the company’s operating results.
Source: company announcement
Zhong Nanshan “calls the name” Baiyunshan shares soar
Baiyunshan official Weibo recently released the news that Zhong Nanshan, an academic at the Chinese Academy of Engineering, said at a seminar recently that Banlangen particles from the Baiyunshan compound are effective against the novel corona virus. On October 16, many media reported on this.
It is reported that in the seminar that day, academic Zhong Nanshan mentioned in the report that after more than ten years of joint research, Baiyunshan Isatis root can prevent viruses from entering cells and has anti-inflammatory effects, that is , Baiyunshan Isatis root can inhibit virus invasion. Regulate inflammation and other pharmacological effects. Since the outbreak of the new corona pneumonia, the research team has attached great importance to the research of the “Medicine of the South” against the new coronavirus, combined with the beneficial experience of clinical practice, and cooperated with the Pharmaceutical Group of Guangzhou to carry out anti-novel coronavirus on 16 listed Chinese patent drugs from its 10 companies. In vitro drug efficacy screening found that Banlangen granules of Baiyunshan compound have inhibitory efficacy in vitro.
Fueled by the news, both Baiyunshan’s A shares and H shares rose sharply on October 16.
Source: Choice
Baiyunshan’s strong performance also drove the anti-flu concept stock trend that day.Xiangxue Pharmaceutical、Shin Kong PharmaceuticalDaily limit,Hongri PharmaceuticalIt rose more than 8%,Sunflower Pharmacist、Baby pumpkinIt went up more than 7%.
Baiyun Mountain Clearance
The conclusion of the investigation is only the result of an in vitro screening test
Baiyunshan issued a clarification announcement on October 18, showing that the company is concerned by recent media reports on the findings of in vitro studies of Banlangen granules of the Baiyunshan compound. In response, the company stated that Guangzhou Baiyunshan Hutchison Whampoa Traditional Chinese Medicine Co., Ltd. (“Baiyunshan Hutchison”) is a 50% joint venture and is not included in the scope of consolidation of the company. The company uses long-term capital investments in it. The equity method is used for accounting. The company is mainly engaged in the production and sale of Chinese patented drugs and drug research and development. The main products include Banlangen granules, Composite Danshen tablets and Composite Banlangen granules.
Baiyunshan said that the relevant conclusions involved in the relevant media reports are only the results of the in vitro detection of anti-novel coronaviruses made by the team of academic Zhong Nanshan on the Banlangen compound granules of the Baiyunshan Hehuang company, and it needs more work on the product in the future.
The announcement also featured the current domestic market for Banlangen products. The advertisement shows that Banlangen products are currently fully competitive products in the domestic market. Banlangen granules and Banlangen compound granules have been approved with a large number of document numbers. Banlangen products are not exclusive products of the company or its affiliates.
According to the announcement, Banlangen Granules and Compound Banlangen Granules currently have 981 approval document numbers and 147 approval document numbers, respectively. In 2019, the sales of domestic urban retail pharmacies were RMB 1,065 million and RMB 430 million, respectively. Both products have the effect of eliminating heat, detoxifying and cooling the blood.
It does not have a significant impact on the performance of the company.
Public information shows that Baiyunshan is mainly engaged in the research, development, manufacture and sale of Chinese and Western patented drugs, chemical raw materials, natural medicines, biomedicine and intermediate chemical raw materials; research and development, production and sale of important health products. It owns 12 established pharmaceutical factories, such as Chen Liji Pharmaceutical Factory, Zhongyi Pharmaceutical, Pan Gaoshou Pharmaceutical, etc. Furthermore, the brands “Wanglaoji” and “Baiyunshan” are also household names.
Regarding the impact of Banlangen products on the performance of listed companies, Baiyunshan said that at present, only Baiyunshan Hehuang Company produces and sells Banlangen products between the company and its subsidiaries and joint ventures.
In 2019, Baiyunshan and Huang Company’s investment income was RMB 67,960,300, which represents about 1.65% of the company’s total profit for the year; Investment income earned in the first half of 2020 was RMB 35,998,200, which is roughly the company’s current profit 1.59% of the total.
The sales revenue of Banlangen Composite Granules produced by Baiyunshan Hutchison Company in 2019 was about RMB 10,910,700, which represents 7.23% of the company’s sales revenue for the year; Sales revenue for the first half of 2020 was approximately RMB 75,546,100, representing the company’s sales revenue for the same period. 8.35%. The sales of Compound Banlangen Granules are not expected to have a significant impact on the company’s operating results.
It is worth mentioning that in the first half of this year, Baiyunshan’s performance was not satisfactory. The semi-annual report shows that in the first half of 2020, the company achieved operating income of RMB 30.47 billion, a year-on-year decrease of 8.61%; The net profit attributable to shareholders of the company was RMB 1.764 billion, a year-on-year decrease of 30.75%.
According to the company, in the first half of 2020, under the influence and impact of the new corona pneumonia epidemic, all business segments of the group were affected to varying degrees, resulting in a year-on-year decrease in results. operational.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in charge: Chen Zhijie
